The paper aims to evaluate the effects of metadoxine on liver function tests in chronic alcohol abusers without a clear alcohol dependence, by means of an open trial carried out in 7 hospitals in Tuscany. The study comprised 72 patients with a daily alcohol intake of at least 80 g for men and 30 g for women, over a period of at least 5 years. The patients were urgently requested to stop drinking, and were randomly divided into 2 groups, of which the first (52 subjects) was treated with metadoxine (500 mg twice a day) and the second (20 subjects) received only some vitamins. Interviews and blood tests were performed 1 and 2 months after the trial began. Statistical calculations were made using the chi-square and Student's tests. Metadoxine induced a more rapid reduction of SGOT and SGPT and, possibly, of Gammagt; these effects were especially evident, and were associated with a significant reduction of MCV, in 20 patients (12 in the first group and 8 in the second) in whom blood test abnormalities were greatest. No unfavorable side effects were observed that could be attributed to the drug. Metadoxine can therefore be considered a valuable resource in the treatment of alcoholic liver disease.